Number (%) of patients with adverse events CTC grade 3 to 4 (unless stated otherwise) during VAD/TAD cycles 1 to 3
| . | Arm A: VAD n = 267 (%) . | Arm B: TAD n = 268 (%) . | P . |
|---|---|---|---|
| Any adverse event | 100 (37) | 132 (49) | .006 |
| Cardiovascular function | 24 (9) | 25 (9) | .89 |
| Coagulation | 2 (1) | 9 (3) | .06 |
| Constitutional symptoms | 22 (8) | 25 (9) | .66 |
| Metabolic | 29 (11) | 24 (9) | .46 |
| Gastrointestinal | 14 (5) | 28 (10) | .03 |
| Pain | 16 (6) | 14 (5) | .70 |
| Neurology | 18 (7) | 35 (13) | .01 |
| Neurology CTC 2-4 | 56 (21) | 83 (31) | .008 |
| . | Arm A: VAD n = 267 (%) . | Arm B: TAD n = 268 (%) . | P . |
|---|---|---|---|
| Any adverse event | 100 (37) | 132 (49) | .006 |
| Cardiovascular function | 24 (9) | 25 (9) | .89 |
| Coagulation | 2 (1) | 9 (3) | .06 |
| Constitutional symptoms | 22 (8) | 25 (9) | .66 |
| Metabolic | 29 (11) | 24 (9) | .46 |
| Gastrointestinal | 14 (5) | 28 (10) | .03 |
| Pain | 16 (6) | 14 (5) | .70 |
| Neurology | 18 (7) | 35 (13) | .01 |
| Neurology CTC 2-4 | 56 (21) | 83 (31) | .008 |
Only adverse events with an incidence > 5% (except coagulation) are reported. Expected events such as diarrhea and mucositis were not recorded on the CRFs.
VAD indicates vincristine, adriamycin, and dexamethasone; TAD, thalidomide, adriamycin, and dexamethasone; and CTC, common toxicity criteria.